A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Recruiting · NCT07005102 · Registry updated 2026-10-05

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer	neoplasm	Recruiting	Phase 2 / Phase 3	2026-10-05		NCT07005102

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AbbVie	340

65 results · Page 1 of 3

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Asan Medical Center /ID# 275600	Seoul	South Korea	1
Austin Health /ID# 275505	Heidelberg	Australia	1
AZ-Delta. /ID# 275753	Roeselare	Belgium	1
Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 277808	Perugia	Italy	1
Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 275215	Orbassano	Italy	1
Cancer Hospital - Chinese Academy of Medical Sciences /ID# 275631	Beijing	China	1
CHU de Liege /ID# 277971	Liège	Belgium	1
Chungbuk National University Hospital /ID# 275768	Cheongju-si	South Korea	1
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 284734	Irvine	United States	1
City Of Hope - Upland /ID# 284650	Upland	United States	1
City of Hope National Medical Center /ID# 282241	Duarte	United States	1
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 280103	Roma	Italy	1
Fujian Province Cancer Hospital /ID# 274913	Fuzhou	China	1
Hospital Clinic de Barcelona /ID# 275476	Barcelona	Spain	1
Hospital Cuf Porto /ID# 275395	Porto	Portugal	1
Hospital General Universitario Gregorio Maranon /ID# 275475	Madrid	Spain	1
Hospital Universitario 12 de Octubre /ID# 277698	Madrid	Spain	1
Inje University Haeundae Paik Hospital /ID# 275388	Busan	South Korea	1
Instituto Valenciano de Oncologia /ID# 275471	Valencia	Spain	1
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 274948	Rome	Italy	1
Ironwood Cancer and Research Centers - Chandler /ID# 275443	Chandler	United States	1
Jessa Ziekenhuis - Campus Virga Jesse /ID# 275585	Hasselt	Belgium	1
Juntendo University Hospital /ID# 276424	Bunkyo-ku	Japan	1
Kaiser Permanente Moanalua Medical Center /ID# 275942	Honolulu	United States	1
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 275293	Kaohsiung City	Taiwan	1

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Clinical trials

Organizations

Research sites